Pliant Therapeutics
Innovating Integrin-Based Therapies
South San Francisco, CA, United States
Pliant Therapeutics is a company developing treatments for fibrotic diseases.
How We Help
Problem Statement
Pliant Therapeutics aims to address the unmet medical needs in fibrotic diseases, solid tumors, and muscular dystrophies by developing novel integrin-based therapies that are potentially safer and more effective than existing treatments.
Core Technology
Proprietary integrin discovery platform
Key Differentiators
Leadership in the development of integrin-based therapeutics, proprietary drug discovery platform, focus on understanding and applying the role of integrins in diseases to unlock potentially safer and more effective therapies, and a precision medicine approach.
Clinical Focus
Fibrotic diseases, solid tumors, muscular dystrophies
Product Stage
Beta
Company Info
- Business Model
- Clinical-stage Biopharmaceutical
- Founded
- 2015
- Total Funding
- 1,100,000,000
- Website
- pliantrx.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Bexotegrast: FDA Fast Track + Orphan Drug designation (PSC, IPF). INTEGRIS-PSC Phase 2a positive (320mg well-tolerated, improved liver stiffness p<0.05, improved ALP p<0.05 at 24 weeks, followed through 40 weeks). PLN-101095: Phase 1a/1b interim data shows 40% response rate (4/10 ICI-refractory: 1 CR, 3 PR) in secondary-refractory patients with median 15-month durability. Multiple tumor types responding: cholangiocarcinoma, melanoma, HNSCC, NSCLC.
MedStartr Index Score
?What do you think of Pliant Therapeutics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.